Psoriasis Clinical Trial
Official title:
Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis
Several studies have documented an essential role for interleukin-10 (IL-10) in preventing
prolonged and exaggerated immune responses to antigens and irritants. Psoriasis, a
relatively common disease, is characterized by T cell-mediated inflammation in affected
skin. In this study, the safety, tolerance, immunologic effects, and clinical activity of
subcutaneous (SC) recombinant human (rh) IL-10 will be evaluated in patients with
moderate-to-severe psoriasis. There will be 2 groups of patients, randomized to receive
either 20 ug/kg rhIL-10 SC 3 times weekly (20 patients) or SC placebo (10 patients). This
double-blind phase will continue for a total of 12 weeks and the principal evaluation will
be the comparison between baseline and 12 week Psoriasis Area Severity Index (PASI) scores.
Patients will come for an initial screening visit at day 0, and at weeks 1, 2, 4, 6, 8, and
12, with follow-up visits at weeks 16 and 20.
All patients will be offered rhIL-10 at 12 weeks (following the blinded portion of the study
protocol). Patients initially receiving active medication who wish to continue rhIL-10
therapy will be kept on the drug. This open-label portion of the study will continue for an
additional 12 weeks. Patients continuing with active drug will be evaluated at weeks 14, 16,
20, and 24.
Skin disease activity and toxicity will be assessed and recorded throughout the study. In
addition, research studies will include functional assays to assess cytokine secretion and
immunologic function of peripheral blood cells and immunohistochemical characterization of
the inflammatory cells in skin.
Several studies have documented an essential role for interleukin-10 (IL-10) in preventing
prolonged and exaggerated immune responses to antigens and irritants. Psoriasis, a
relatively common disease, is characterized by T cell-mediated inflammation in affected
skin. In this study, the safety, tolerance, immunologic effects, and clinical activity of
subcutaneous (SC) recombinant human (rh) IL-10 will be evaluated in patients with
moderate-to-severe psoriasis. There will be 2 groups of patients, randomized to receive
either 20 (micro)g/kg rhIL-10 SC 3 times weekly (20 patients) or SC placebo (10 patients).
This double-blind phase will continue for a total of 12 weeks and the principal evaluation
will be the comparison between baseline and 12 week Psoriasis Area Severity Index (PASI)
scores. Patients will come for an initial screening visit at day 0, and at weeks 1, 2, 4, 6,
8, and 12, with follow-up visits at weeks 16 and 20.
All patients will be offered rhIL-10 at 12 weeks (following the blinded portion of the study
protocol). Patients initially receiving active medication who wish to continue rhIL-10
therapy will be kept on the drug. This open-label portion of the study will continue for up
to an additional 12 weeks. Patients continuing with active drug will be evaluated at weeks
14, 16, 20, and 24.
Skin disease activity and toxicity will be assessed and recorded throughout the study. In
addition, research studies will include functional assays to assess cytokine secretion and
immunologic function of peripheral blood cells and immunohistochemical characterization of
the inflammatory cells in skin.
;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
| Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
| Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
| Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
| Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
| Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
| Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
| Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
| Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
| Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
| Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
| Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
| Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
| Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
| Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
| Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
| Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
| Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
| Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
| Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |